Josh Schimmer

Stock Analyst at Evercore ISI Group

(4.86)
# 97
Out of 4,495 analysts
89
Total ratings
64.56%
Success rate
54.92%
Average return

36 Stocks

Longboard Pharmaceuticals
Jul 2, 2024
Maintains: Outperform
Price Target: $57$80
Current: $35.95
Upside: +122.53%
BridgeBio Pharma
Jul 1, 2024
Reiterates: Overweight
Price Target: $70
Current: $26.19
Upside: +167.28%
Insmed
Jun 21, 2024
Maintains: Outperform
Price Target: $42$75
Current: $75.97
Upside: -1.28%
Cabaletta Bio
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $7.09
Upside: +605.22%
Zura Bio
Jun 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.49
Upside: -
Avidity Biosciences
Jun 12, 2024
Maintains: Outperform
Price Target: $40$45
Current: $45.12
Upside: -0.27%
Crinetics Pharmaceuticals
May 14, 2024
Reiterates: Overweight
Price Target: $65
Current: $52.66
Upside: +23.43%
Mirum Pharmaceuticals
May 9, 2024
Reiterates: Overweight
Price Target: $40
Current: $39.49
Upside: +1.29%
Janux Therapeutics
May 9, 2024
Reiterates: Overweight
Price Target: $100
Current: $44.68
Upside: +123.81%
CG Oncology
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $35.22
Upside: +112.95%
Xenon Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $65
Current: $42.73
Upside: +52.12%
Rocket Pharmaceuticals
Feb 27, 2024
Maintains: Overweight
Price Target: $65
Current: $22.82
Upside: +184.84%
Rallybio
Dec 21, 2023
Maintains: Outperform
Price Target: $18$15
Current: $1.34
Upside: +1,019.40%
Krystal Biotech
Dec 13, 2023
Maintains: Overweight
Price Target: $160$180
Current: $203.66
Upside: -11.62%
Ventyx Biosciences
Nov 10, 2023
Downgrades: In-Line
Price Target: $43$5
Current: $2.55
Upside: +96.08%
4D Molecular Therapeutics
Oct 24, 2023
Initiates: Overweight
Price Target: $32
Current: $14.40
Upside: +122.22%
Erasca
Jun 6, 2023
Maintains: Outperform
Price Target: $20$11
Current: $2.95
Upside: +272.88%
Neurocrine Biosciences
Nov 14, 2022
Downgrades: In-Line
Price Target: $140$130
Current: $145.69
Upside: -10.77%
Regeneron Pharmaceuticals
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $1,063.60
Upside: -28.54%
Spero Therapeutics
Sep 23, 2022
Upgrades: Outperform
Price Target: $2$8
Current: $1.40
Upside: +471.43%
Zymeworks
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $9.78
Upside: +53.37%
Viracta Therapeutics
Mar 25, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.55
Upside: -
Cullinan Oncology
Feb 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $18.29
Upside: -
BeyondSpring
Dec 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -
REGENXBIO
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $12.58
Upside: -
Madrigal Pharmaceuticals
Nov 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $287.24
Upside: -
bluebird bio
Jun 19, 2018
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Incyte
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $65.87
Upside: -
Ionis Pharmaceuticals
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $47.82
Upside: -
Voyager Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $8.37
Upside: -
Denali Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $21.46
Upside: -
uniQure
Nov 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $7.74
Upside: -
Boundless Bio
Oct 16, 2017
Downgrades: In-Line
Price Target: n/a
Current: $3.56
Upside: -
Theravance Biopharma
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.57
Upside: -
BioMarin Pharmaceutical
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $84.09
Upside: -
AbbVie
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $172.32
Upside: -